Anti-drug monoclonal antibodies antagonize toxic effect more than anti-tumor activity of doxorubicin.
Monoclonal antibodies (MAbs) able to bind epitope(s) of drug molecule can interfere with the biologic action of the drug. This is known and already exploited in some instances of practical relevance, as in the reversal of the digoxin effect. Similar antidotal action is exhibited by MAbs reacting with a cytotoxic antibiotic, doxorubicin (DXR), and in such a way as to induce differential neutralization of drug action. Indeed, within certain limits, the cytotoxic action of DXR in vitro as well as in vivo is more effectively neutralized on normal than on tumor cells, with consequent increase in therapeutic index.
Balsari
A
A
Department of Biomedical Sciences and Biotechnologies, University of Brescia, Italy.
Ménard
S
S
Colnaghi
M I
MI
Ghione
M
M
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D003433:Crosses, Genetic; D004317:Doxorubicin / Q000276:immunology* / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D007941:Leukemia P388 / Q000188:drug therapy*; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D008815:Mice, Inbred Strains
D000911:Antibodies, Monoclonal; D004317:Doxorubicin